^
Association details:
Evidence:
Evidence Level:
Resistant: D – Preclinical
New
Source:
Title:

FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation

Excerpt:
CRC cells containing FBW7-inactivating mutations are insensitive to clinically used multi-kinase inhibitors of RAS/RAF/MEK/ERK signaling, including regorafenib and sorafenib....Together, our results demonstrate FBW7 mutational status as a key genetic determinant of CRC response to targeted therapies...
DOI:
10.1038/onc.2016.247
Evidence Level:
Resistant: D – Preclinical
New
Source:
Title:

FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation

Excerpt:
All 8 FBW7-mutant CRC cell lines were substantially less sensitive to regorafenib compared to 8 FBW7-wild-type (WT) cell lines, as indicated by higher inhibitory concentration 50 (IC50) (Fig. 1B and Table S1).
DOI:
10.1038/onc.2016.247